Form 13-F position report

ALLOGENE THERAPEUTICS INC

Reported by VANGUARD GROUP INC

ALLO CUSIP 019770106 Manager CIK 0000102909

Reported 6,602,306 shares, up 645,613 (10.8%) from the prior quarter.

Reported value -18.1%; share count 10.8% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2021
Shares 6,602,306 Quarter-end amount reported
Reported value $172,189,000 Fair value at quarter end
Consecutive quarters held 11 Through Q2 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 210271000
2021-06-30 172189000
2021-09-30 172080000
2021-12-31 100588000
2022-03-31 61529000
2022-06-30 95830000
2022-09-30 77362000
2022-12-31 45698239
2023-03-31 36088360
2023-06-30 37282420
2023-09-30 33563338
2023-12-31 28988948
2024-03-31 36687811
2024-06-30 19095902
2024-09-30 23317557
2024-12-31 17041474
2025-03-31 11778627
2025-06-30 9332815
2025-09-30 11185755
2025-12-31 12674704

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ALLOGENE THERAPEUTICS INC held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Added 9,251,609 +230,839 (2.6%) < 0.01% $12,674,704 2026-01-29
Q3 2025 Added 9,020,770 +761,642 (9.2%) < 0.01% $11,185,755 2025-11-07
Q2 2025 Added 8,259,128 +191,575 (2.4%) < 0.01% $9,332,815 2025-08-11
Q1 2025 Added 8,067,553 +66,861 (0.8%) < 0.01% $11,778,627 2025-05-09
Q4 2024 Reduced 8,000,692 -327,007 (-3.9%) < 0.01% $17,041,474 2025-02-11
Q3 2024 Added 8,327,699 +132,033 (1.6%) < 0.01% $23,317,557 2024-11-13
Q2 2024 Reduced 8,195,666 -11,898 (-0.1%) < 0.01% $19,095,902 2024-08-13
Q1 2024 Reduced 8,207,564 -823,261 (-9.1%) < 0.01% $36,687,811 2024-05-10
Q4 2023 Reduced 9,030,825 -1,556,979 (-14.7%) < 0.01% $28,988,948 2024-02-14
Q3 2023 Added 10,587,804 +3,086,311 (41.1%) < 0.01% $33,563,338 2023-11-14
Q2 2023 Added 7,501,493 +196,157 (2.7%) < 0.01% $37,282,420 2023-08-14
Q1 2023 Added 7,305,336 +40,115 (0.6%) < 0.01% $36,088,360 2023-05-15
Q4 2022 Added 7,265,221 +102,139 (1.4%) < 0.01% $45,698,239 2023-02-10
Q3 2022 Reduced 7,163,082 -1,243,065 (-14.8%) < 0.01% $77,362,000 2022-11-14
Q2 2022 Added 8,406,147 +1,652,167 (24.5%) < 0.01% $95,830,000 2022-08-12
Q1 2022 Added 6,753,980 +12,141 (0.2%) < 0.01% $61,529,000 2022-05-13
Q4 2021 Added 6,741,839 +46,119 (0.7%) < 0.01% $100,588,000 2022-02-14
Q3 2021 Added 6,695,720 +93,414 (1.4%) < 0.01% $172,080,000 2021-11-12
Q2 2021 Added 6,602,306 +645,613 (10.8%) < 0.01% $172,189,000 2021-08-13
Q1 2021 Added 5,956,693 +170,216 (2.9%) < 0.01% $210,271,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

197 managers reported ALLOGENE THERAPEUTICS INC for Q2 2021.

Managers reporting ALLOGENE THERAPEUTICS INC in Q2 2021.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 7,021,939 +751,861 < 0.01% $183,132,000 11 qtrs
VANGUARD GROUP INC This report Added 6,602,306 +645,613 < 0.01% $172,189,000 11 qtrs
Capital Research Global Investors Reduced 5,404,300 -7,259,713 0.03% $140,944,000 11 qtrs
PRIMECAP MANAGEMENT CO CA Added 3,577,030 +2,271,630 0.06% $93,289,000 3 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 3,535,184 +78,431 < 0.01% $92,198,000 11 qtrs
Capital International Investors Reduced 3,525,114 -3,073,922 0.02% $91,935,000 11 qtrs
ALLIANCEBERNSTEIN L P Added 3,166,630 +625,071 0.03% $82,586,000 11 qtrs
STATE STREET CORPORATION Added 3,004,900 +671,104 < 0.01% $78,368,000 11 qtrs
JPMorgan Chase & Co Added 2,484,735 +102,868 < 0.01% $64,802,000 11 qtrs
Capital World Investors Reduced 2,246,577 -26 < 0.01% $58,591,000 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2021
Filed
August 13, 2021
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
96,682
None
6,505,624

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.